Original paper
P-039: Adaptation of a myeloma minimal residual disease multi-parametric flow assay for real world practice
Abstract
Background Achieving minimal residual disease (MRD) negativity during treatment for multiple myeloma (MM) is prognostic for disease free and overall survival. There is limited testing of MRD outside clinical trials, and the need to process fresh samples for multicolour flow cytometry (MCF) assays presents a challenge to laboratories. We set up an 8-colour MCF assay, in collaboration with a reference centre (Leeds HMDS), to identify and quantify...
Paper Details
Title
P-039: Adaptation of a myeloma minimal residual disease multi-parametric flow assay for real world practice
Published Date
Oct 1, 2021
Volume
21
Pages
S59 - S60
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History